C-MORE

Capturing multi-organ effects of COVID-19.

COVID-CNS

The COVID-19 Clinical Neuroscience Study.

DFP

Deep and Frequent Phenotyping: Combinatorial Biomarkers for Dementia Experimental Medicine.

DPUK Tau (PREVENT Sub study)

Assessing Models of AD risk and progression in existing cohorts using Tau PET imaging in combination with prospective follow-up.

ENCRYPT (PREVENT Sub study)

The Entorhinal CoRtex-hippocampal circuit in PREVENT (ENCRYPT) study.

MND

A study to characterise C9orf72 patients and asymptomatic carriers.

NTAD

New Therapeutics in Alzheimer’s Disease – MEG biomarker platform development.

PREVENT

Previous research suggests there can be a variety of markers of dementia before the presentation of symptoms. The Prevent study aims to investigate participants between the ages of 40 and 59 years old in their exposure to risk factors before dementia onset. It is a longitudinal and cross-sectional study which means that the study is ongoing and will take a snapshot of participants at consecutive 2 – 6-year time gaps throughout their middle age. At each of these visits, a series of assessments are carried out to investigate a wide range of risk factors, including cognitive performance, biomarkers, and brain structural/functional changes. The study is thorough, aiming to identify any other risk factors with possible links to dementia onset, including a family history of dementia, life stressors, drug use, alcohol intake, sleep quality, exposure to contact sports and physical activity. The study has been running at the Clinical Research Facility (CRF) since 2017, and participants will be coming up to their 3^rd visit as we approach 2023. The CRF is incredibly grateful to all Prevent participants who have already volunteered their time and contributed so much to the trial.

RADAR-AD

Remote assessment of Disease and Relapse – Alzheimer’s Disease.

ZOGENIX

The effect of seven day fenfluramine administration on cognition in healthy volunteers.

APFEMA

Analysing Patients’ Facial Expressions to improve Mood Assessment.

ATP

A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS-penetrant PX27 receptor antagonist, JNJ-54175446, in people with major depressive disorder, an incomplete response to monoaminergic antidepressant drugs, and a biomarker profile of active PX27 signalling.

Janssen Adolescent

This study aims to find out whether seltorexant (JNJ-42847972) could be used as an add-on treatment, along with your current anti-depressant medication, to treat depression (Major Depressive Disorder) that has not responded to current antidepressant medication (SSRI) and psychotherapy.

LQD

Lithium and quetiapine for treatment resistant depression.

PAX-D

Randomised, placebo-controlled trial evaluating the efficacy and mechanism of Pramipexole as add-on treatment for people with treatment resistant depression.

RELAKS

Reward, Emotion, Learning, and Ketamine study.

RESTAND

The effects of PF-04995274 on emotional processing in unmedicated depressed patients.

RESTART

The effects of PF-04995274 on emotional processing in treatment-resistant, medicated, depressed patients.

SUSTAIN-3

An open-label long-term extension safety study of intranasal esketamine in treatment-resistant depression safety and sustenance of esketamine treatment response with repeated doses at intervals determined by symptom severity (SUSTAIN-3).

ALKERMES

A study to evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness.

PATTERN

The Physical and menTal healTH – ExploRatioN study.

BI CACT

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 week tratment period in patients with Schizophrenia.

Biogen

A phase 2, randomised, double-blind, multiple-dose, placebo-controlled study to evaluate the safety and efficacy of BIIB104 in Subjects with Cognitive Impairment Associated with Schizophrenia (CIAS).

SINAPPS2

A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis.